###### Strengths and limitations of this study

-   The study has a large sample size because of its population-based design.

-   National Health Insurance Research Database covers a highly representative sample of Taiwan's general population.

-   All insurance claims should be scrutinised by medical reimbursement specialists and peer review.

-   Lack of individual laboratory data and related exposure history.

-   There may have some uncontrolled confounding factors and potential biases in this retrospective cohort study.

Introduction {#s1}
============

Glaucoma is the leading cause of irreversible blindness worldwide.[@R1] In Taiwan, the prevalence and the incidence of open angle glaucoma (OAG) and angle closure glaucoma (ACG) are the highest among people of advanced age.[@R2] There are various commercially available glaucoma medications that can be prescribed by a clinician.[@R3] In the past three decades, topical beta-blockers have served as first-line drugs for glaucoma treatment.[@R4] According to the policy of the National Health Insurance (NHI) of Taiwan, topical beta-blockers constitute first-line treatment for patients with glaucoma without contraindication to beta-blockers.[@R5] Patients with glaucoma in Taiwan are highly comorbid with cardiovascular disease of either the OAG or ACG type.[@R6] Several studies have reported on the cardiovascular and respiratory safety of the long-term use of topical beta-blockers.[@R8] However, their findings have been conflicting. For example, both the Barbados Eye Study and Blue Mountains Eye Study have observed an association between mortality and beta-blockers.[@R8] Similarly, a retrospective cohort analysis also observed a relationship between adverse outcomes and the use of topical beta-blockers for glaucoma therapy.[@R10] Conversely, the Rotterdam Study and EPIC-Norfolk Cohort Study have reported that topical beta-blockers do not appear to be associated with excess cardiovascular mortality.[@R4]

To clarify this important issue, we conducted a nationwide population-based cohort study by analysing data from Taiwan's NHI Research Database (NHIRD) to determine the relationship between topical beta-blocker use and risks of cardiovascular and respiratory diseases in patients with glaucoma in the population of Taiwan. To the best of our knowledge, this is the first study to use a large claims database from an Asian country to examine the long-term potential complications of cardiovascular and respiratory diseases among patients with glaucoma using topical beta-blockers.

Methods {#s2}
=======

Patient and public involvement {#s2-1}
------------------------------

This population-based retrospective cohort study was conducted using the database of Taiwan's NHI programme. The NHI programme was launched on March 1995, and it covers approximately 99% of the 23.74 million people living in Taiwan.[@R12] The NHIRD was set up on 1 March 1995 by the NIH Administration and is maintained by the National Health Research Institute of Taiwan. The Longitudinal Health Insurance Database (LHID) is a part of the NHIRD. The NHIRD is a large computerised database that contains the data of all insured persons. It includes data on background conditions and diagnoses as well as data on detailed health services such as those on medications, examinations and operations. The LHID includes all medical claims data from 1996 to 2011 of 1 million beneficiaries who were randomly selected from the 23.74 million beneficiaries of the NHI. More details on the NHI programme and the LHID are available from other sources.[@R13]

Sample participants {#s2-2}
-------------------

The study population comprised patients who were newly diagnosed with glaucoma. They were identified from the LHID2000 (International Classification of Diseases (ICD)-9-CM code 365) data obtained from January 2000 to December 2010. The patients with glaucoma were divided into two cohorts according to whether they used a beta-blocker or combination drug (BBCD). The BBCD cohort included patients who had received a BBCD therapy for at least 28 days; the non-BBCD cohort included patients who had not received a BBCD before and during follow-up. The index date of the BBCD cohort was the 28th day; the index date for non-BBCD patients was a randomly selected month and day with the same index year of the matched BBCD patents. Patients aged less than 20 years who had incomplete age or sex information were excluded from both cohorts. Individuals without BBCD use were selected from the LHID2000 and matched to the BBCD cohort at a ratio of 1:1 based on the propensity score through nearest neighbour matching, initially to the eighth digit and then as required to the first digit.[@R15] Therefore, matches were first made within a calliper width of 0.0000001, and then the calliper width was increased for unmatched cases to 0.1. We reconsidered the matching criteria and performed a rematch (greedy algorithm). For each glaucoma patient on BBCD use, the corresponding comparisons were selected based on the nearest propensity score. The propensity score was calculated using a logistic regression model to estimate the probability of the BBCD status. The model was based on the baseline variables of age, gender, index year and comorbidities of hypertension, hyperlipidaemia, diabetes mellitus, chronic obstructive pulmonary disease (COPD), asthma, chronic kidney disease, pneumonia (ICD-9-CM code 486), acute respiratory failure (ICD-9-CM code 518.81), stroke (ICD-9-CM codes 430--438) and coronary artery disease (CAD) (ICD-9-CM codes 410--414), and glaucoma medications of prostaglandin analogue (PGA), carbonic anhydrase inhibitor (CAI), alpha (α)-agonists and pilocarpine.

Outcome measurement {#s2-3}
-------------------

The study endpoints were pneumonia, acute respiratory failure, stroke (including haemorrhagic and ischaemic stroke) and CAD. All included patients were followed up from the index date until death, withdrawal from the NHI programme, the end of 2011 or the occurrence of the endpoint.

Statistical analysis {#s2-4}
--------------------

We compared the proportions of demographic data, comorbidities and medications between the BBCD and non-BBCD cohorts using Pearson's χ^2^ test for categorical variables and Mann-Whitney U test for continuous variables. The overall incidence densities of the endpoints (including pneumonia, acute respiratory failure, stroke and CAD) were measured for both cohorts. To address the concern of constant proportionality, we examined the proportional hazard model assumption by using a test of scaled Schoenfeld residuals. The results showed that there was no significant relationship between Schoenfeld residuals for BBCD and follow-up time (p value =0.05, 0.08, 0.66, 0.10, 0.57, respectively) in the model evaluating the pneumonia, stroke, haemorrhagic stroke, ischaemic stroke and CAD risk. The proportional hazard model assumption was also applied by using a test of scaled Schoenfeld residuals. In the model evaluating the acute respiratory failure risk throughout overall follow-up period, the test results revealed a significant relationship between Schoenfeld residuals for BBCD and follow-up time, suggesting the proportionality assumption was violated (p value =0.02). In the subsequent analyses, we stratified the follow-up duration to deal with the violation of proportional hazard assumption. Univariable and multivariable Cox proportional hazards regression models were used to estimate the HRs, 95% CIs and 98.75% CIs of endpoints of the BBCD cohort in relation to the non-BBCD cohort. The multivariable models were also used by adjustment of age, gender and comorbidities of hypertension, hyperlipidaemia, diabetes mellitus, COPD, asthma, CKD, pneumonia, acute respiratory failure, stroke and CAD, and the use of glaucoma medications (PGA, CAI, α-agonist and pilocarpine). The Bonferroni method of multiple comparisons was set the p value at 0.0125. The BBCD use was quantified as a binary variable every 6 months. Due to frequency variations in BBCD use among patients with glaucoma during the study period, BBCD were considered as time-dependent covariates in the Cox proportional hazards models to compute the HRs and their 95% CI and 98.75% CI for outcome in BBCD cohort when compared with non-BBCD cohort. All data analyses were performed using SAS V.9.4 software. The level of significance was set at 0.05, and the tests were two-tailed.

Results {#s3}
=======

We included 6168 patients with glaucoma in both the BBCD and non-BBCD cohorts; the distributions of age, gender and comorbidities were similar in both cohorts ([table 1](#T1){ref-type="table"}). The median (IQR) ages in the BBCD cohort and the non-BBCD cohort were 60.5 (IQR=47.7--70.4) and 60.6 (IQR=47.7--71.4) years, respectively. In both cohorts, approximately 29% patients were aged ≤49 years, and approximately 51% of the patients were women. In both cohorts, the major comorbidity was hypertension (52.5% vs 49.6%), followed by hyperlipidaemia (37.5% vs 35.8%) and history of CAD (26.6% vs 25.8%). The use of the medications PGA, CAI, α-agonist and pilocarpine was also similar in the BBCD cohort than in the non-BBCD cohort.

###### 

Demographic characteristics of study patients and the propensity score-matched sample by medicine use

                                          Beta-blocker or combination drug use                              
  --------------------------------------- -------------------------------------- ------------------- ------ ------
  Age, median (IQR)                       60.6 (47.7--71.4)                      60.5 (47.7--70.4)          
  Stratify age                                                                                              
   20--49                                 1772                                   28.7                1812   29.4
   50--64                                 1928                                   31.3                1949   31.6
   65+                                    2468                                   40                  2407   39
  Gender                                                                                                    
   Women                                  3112                                   50.5                3135   50.8
   Men                                    3056                                   49.6                3033   49.2
  Comorbidity                                                                                               
   Hypertension                           3240                                   52.5                3058   49.6
   Hyperlipidaemia                        2313                                   37.5                2207   35.8
   Diabetes mellitus                      1452                                   23.5                1363   22.1
   COPD                                   1038                                   16.8                1013   16.4
   Asthma                                 588                                    9.53                561    9.1
   CKD                                    535                                    8.67                493    7.99
   History of pneumonia                   206                                    3.34                204    3.31
   History of acute respiratory failure   38                                     0.62                41     0.66
   History of coronary artery disease     1642                                   26.6                1588   25.8
   History of stroke                      474                                    7.68                426    6.91
  Other glaucoma medications                                                                                
   PGA                                    421                                    6.83                504    8.17
   CAI                                    366                                    5.93                412    6.68
   Alpha agonist                          575                                    9.32                593    9.61
   Pilocarpine                            909                                    14.7                818    13.3

CAI, carbonic anhydrase inhibitor; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PGA, prostaglandin analogue.

The BBCD cohort had a slightly higher incidence rate of acute respiratory failure (10.8 per 1000 person-years) than the non-BBCD cohort (9.79 per 1000 person-years; adjusted HR (aHR)=1.16, 95% CI 1.00 to 1.34) ([table 2](#T2){ref-type="table"}). The multivariable analyses also showed that the BBCD cohort had a lower risk of CAD (aHR=0.93, 95% CI 0.87 to 0.99) than the non-BBCD cohort. Additionally, regarding the risk of the endpoints, the aHR was significantly higher for stroke (aHR=1.39, 95% CI 1.23 to 1.58) and ischaemic stroke (aHR=1.44, 95% CI 1.26 to 1.64; aHR=1.44, 98.75% CI 1.21 to 1.71). After considering the multiplicative interaction of age and sex, the BBCD cohort do not have significantly higher risk of all outcomes than the non-BBCD cohort.

###### 

Comparison of incidence and HRs of outcomes by medication status

                              Beta-blocker or combination drug use                                                                                                                                        
  --------------------------- -------------------------------------- -------- ------ ------ --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  Pneumonia                   586                                    34 399   17.0   595    34 257                17.4                  1.02 (0.91 to 1.15)   1.06 (0.94 to 1.19)   1.06 (0.92 to 1.23)   1.19 (0.58 to 2.45)
  Acute respiratory failure   345                                    35 242   9.79   377    35 074                10.8                  1.10 (0.95 to 1.27)   1.16 (1.00 to 1.34)   1.16 (0.96 to 1.39)   1.45 (0.54 to 3.85)
   ≤5                         233                                    24 591   9.48   241    24 727                9.75                  1.03 (0.86 to 1.23)   1.13 (0.94 to 1.36)   1.13 (0.90 to 1.43)   1.55 (0.46 to 5.20)
   \>5                        112                                    10 651   10.5   136    10 346                13.1                  1.25 (0.98 to 1.61)   1.19 (0.93 to 1.53)   1.19 (0.87 to 1.64)   1.27 (0.23 to 7.11)
  Stroke                      441                                    34 316   12.9   549    33 683                16.3                  1.27 (1.12 to 1.44)   1.39 (1.23 to 1.58)   1.39 (1.19 to 1.64)   0.73 (0.34 to 1.57)
   Haemorrhagic stroke        62                                              1.81   65                           1.93                  1.07 (0.75 to 1.51)   1.14 (0.80 to 1.61)   1.14 (0.73 to 1.77)   0.55 (0.09 to 3.33)
   Ischaemic stroke           379                                    11.0     484    14.4   1.30 (1.14 to 1.49)   1.44 (1.26 to 1.64)   1.44 (1.21 to 1.71)   0.80 (0.35 to 1.86)                         
  CAD                         1930                                   27 123   71.2   1823   27 431                66.5                  0.93 (0.88 to 1.00)   0.93 (0.87 to 0.99)   0.93 (0.86 to 1.01)   0.85 (0.61 to 1.18)

\*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0125.

\*Incidence rate, per 1000 person-years.

†Multivariable analysis includes age, gender and comorbidities of hypertension, hyperlipidaemia, diabetes mellitus, COPD, asthma, CKD, pneumonia, acute respiratory failure, stroke and CAD, and the use of the medications PGA, CAI, alpha agonist and pilocarpine.

‡Multivariable analysis includes age, gender, multiplicative interaction of age and sex and comorbidities of hypertension, hyperlipidaemia, diabetes mellitus, COPD, asthma, CKD, pneumonia, acute respiratory failure, stroke and CAD, and the use of the medications PGA, CAI, alpha agonist and pilocarpine.

CAD, coronary artery disease; CAI, carbonic anhydrase inhibitor; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PGA, prostaglandin analogue; PY, person-years.

Moreover, the time-dependent regression analysis after adjustment for age, gender and comorbidities of hypertension, hyperlipidaemia, diabetes mellitus, COPD, asthma, CKD, pneumonia, acute respiratory failure, stroke and CAD and the use of the medications PGA, CAI, α-agonist and pilocarpine revealed that BBCD cohorts had higher risk of acute respiratory failure (aHR=1.17, 95% CI 1.01 to 1.35) and ischaemic stroke (aHR=1.44, 95% CI 1.26 to 1.65) ([table 3](#T3){ref-type="table"}). However, after considering the multiplicative interaction of age and sex, the BBCD cohort had no significantly risk of all outcomes than the non-BBCD cohort.

###### 

Comparison of incidence and HRs of outcomes by medication status by Cox proportional hazard model with time-dependent covariates

                              Beta-blocker or combination drug use                                                   
  --------------------------- -------------------------------------- --- --------------------- --------------------- ---------------------
  Pneumonia                   1                                      1   1.02 (0.91 to 1.15)   1.06 (0.92 to 1.23)   1.11 (0.54 to 2.28)
  Acute respiratory failure   1                                      1   1.10 (0.95 to 1.27)   1.17 (1.01 to 1.35)   1.37 (0.51 to 3.64)
  Stroke                      1                                      1   1.27 (1.12 to 1.44)   1.39 (1.23 to 1.58)   0.72 (0.34 to 1.56)
   Haemorrhagic stroke        1                                      1   1.07 (0.75 to 1.51)   1.14 (0.80 to 1.62)   0.79 (0.34 to 1.83)
   Ischaemic stroke           1                                      1   1.30 (1.14 to 1.49)   1.44 (1.26 to 1.65)   0.57 (0.10 to 3.46)
  CAD                         1                                      1   0.93 (0.88 to 1.00)   0.93 (0.87 to 0.99)   0.85 (0.61 to 1.17)

Incidence rate, per 1000 person-years.

\*Multivariable analysis includes age, gender and comorbidities of hypertension, hyperlipidaemia, diabetes mellitus, COPD, asthma, CKD, pneumonia, acute respiratory failure, stroke and CAD, and the use of the medications PGA, CAI, alpha agonist and pilocarpine.

†Multivariable analysis includes age, gender, multiplicative interaction of age and sex and comorbidities of hypertension, hyperlipidaemia, diabetes mellitus, COPD, asthma, CKD, pneumonia, acute respiratory failure, stroke and CAD, and the use of the medications PGA, CAI, alpha agonist and pilocarpine.

CAD, coronary artery disease; CAI, carbonic anhydrase inhibitor; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PGA, prostaglandin analogue; PY, person-years.

Discussion {#s4}
==========

Our study demonstrated that in a large Taiwanese--Chinese population, topical beta-blocker use would not increase the risks of cardiovascular and respiratory diseases in patients with glaucoma. Topical beta-blockers remain a primary glaucoma medication.[@R16] It is contraindicated in individuals with a previous myocardial infarction, a history of arrhythmia or bradycardia and pulmonary issues such as COPD or emphysema.[@R11] Conflicting results on the association between topical beta-blocker use and cardiovascular mortality have been reported. The Blue Mountains Eye Study showed increased cardiovascular mortality in persons with previously diagnosed glaucoma.[@R8] The Barbados Eye Study demonstrated that cardiovascular mortality tended to increase in persons with previously diagnosed or treated OAG and ocular hypertension in the black population; the excess mortality associated with timolol maleate treatment of OAG was also observed in a white population.[@R9] Similarly, a retrospective cohort study was conducted using data from the UK Clinical Practice Research Datalink database.[@R10] That study suggested that the introduction of beta-blockers in patients with glaucoma who later discontinue their use is associated with an increase in the use of healthcare resources (such as a higher number of general practitioner visits and hospitalisations). This may be indicative of a potential relationship between adverse outcomes and the use of topical beta-blockers for glaucoma therapy.[@R10] Conversely, the Rotterdam Study and the EPIC-Norfolk Cohort Study have showed that topical beta-blockers are not associated with excess cardiovascular mortality.[@R4] Our study corroborates the results of the Rotterdam Study and EPIC-Norfolk Cohort Study with regard to the risk of CAD.

With regard to topical beta-blockers and the risk of pulmonary disease, the aforementioned retrospective cohort study conducted using the UK database[@R10] reported a significant increase in respiratory event rates postindex versus preindex in patients who discontinued beta-blocker use and patients who did not use beta-blockers, but not in patients who continued using beta-blockers. Our results revealed that topical beta-blocker use might slightly increase the risk of acute respiratory failure (adjusted HRs=1.16, 95% CI 1.00 to 1.34); however, after considering the multiplicative interaction of all potential factors, topical beta-blocker is not associated with higher risk of respiratory disease. Nonetheless, our results cannot be directly compared with the aforementioned one because of our different study design. For example, we included pneumonia and acute respiratory failure as comorbidities. A future longitudinal prospective study must be conducted for further clarification of this important issue-.

Another interesting finding of this study is that topical beta-blocker potentially increases the risk of stroke (aHR=1.39, 95% CI 1.23 to 1.58)---an association that has been rarely discussed in the literature. However, after considering the multiplicative interaction of age and sex, the BBCD cohort had no significantly higher risk of all outcomes than the non-BBCD cohort. The Rotterdam Study investigated associations between the long-term and short-term use of topical beta-blockers and mortality. The cause of mortality was stroke in 3/53 (5.7%) of beta-blocker users and in 58/656 (8.8%) of non-users. We believe that a different study will have a different outcome; thus, with regard to stroke, our results cannot be directly compared with the results of others. With regard to this problem, further observation is required.

Timolol, a non-selective beta-blocker that was approved for use in the USA in 1979, was one of the most frequently prescribed first‐line topical therapies for the reduction of intraocular pressure (IOP) in the 1980s and 1990s.[@R17] Currently, beta-blockers are the first-line treatment facilitating IOP lowering in patients with glaucoma without contraindications in Taiwan. The labelling for timolol and any combination drug with timolol states that coexistent cardiovascular or respiratory disease is a contraindication to their use.[@R18] Timolol-induced interstitial lung disease was reported: a 76-year-old woman presented with productive cough and progressive dyspnoea and hypoxia after starting timolol eye drop use following glaucoma surgery.[@R20] It was also reported that an elderly patient was hospitalised with three side effects of timolol. His condition required intensive care unit admission with mechanical ventilation and temporary transvenous pacing.[@R21] This emphasises the need to raise awareness among clinicians regarding the potential side effects and drug interactions for timolol.

Although our study yielded some important findings, it has some limitations. First, the identification of glaucoma relied entirely on claims data (ICD-9 coding from clinicians), which may be less accurate than individually determined diagnoses by professional ophthalmologists using standardised procedures.[@R22] Second, selection bias was noted in this study. Because the NHIRD database only included patients who sought treatment, those who did not seek treatment may have been recruited into the control cohort.[@R22] However, it is the inherent limitation of this kind of claims database study. Third, most residents in Taiwan are of Chinese ethnicity. Thus, the current results may not directly apply to other ethnic groups. Fourth, preservative-free glaucoma medications are not included in the current health insurance system, and data on them are not available in the current database. Fifth, there is a high likelihood of residual confounding factors, such as smoking, body mass index, severity of glaucoma and systemic disease, were either not available or too complicated to be included in the analysis. Sixth, individuals with the endpoints of this study were more likely to die or withdraw from the study; this limitation is inherent to claims database studies such as ours. Finally, we believe that different study design and methodology might influence the outcomes. It is inadequate to directly compare our study result with others.

Despite the aforementioned limitations, our study has some notable strengths. First, the database is large and has effective sample randomisation[@R22] and we could follow patients over time to assess the relationship between topical beta-blocker use and subsequent onset of outcomes. Second, this dataset includes data on a diverse range of patients with different sociodemographic profiles, unlike some smaller studies that have recruited patients from a specific region, which might not represent the whole population.[@R22] Third, the large sample size of Taiwan's NHIRD database allows for statistically powerful assessments of the relative risk for diseases, including the potential risk factors. Fourth, because glaucoma medications are costly, most patients with glaucoma in Taiwan seek treatment from ophthalmologists. Therefore, the claims database for glaucoma medication usage that was used in this study appears to be reliable.[@R22] Finally, the current study is one of the few studies evaluating the association between topical beta-blocker use and the risk of cardiovascular and respiratory disease in patients with glaucoma by using a large claims database. We believe this finding could enrich the literature and remind the clinicians of the important issue.

Conclusions {#s5}
===========

Although our population-based cohort study indicate that topical beta-blocker is not associated with increased risks of cardiovascular and respiratory diseases in patients with glaucoma, ophthalmologists should still prescribe topical beta-blockers with caution.
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